Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a federal class action by December 8, 2025 [2][5]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [6]. - Following the release of a damaging report by NINGI Research, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [9].
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex Group